OncoSil Medical Limited

ASX:OSL Stock Report

Market Cap: AU$45.4m

OncoSil Medical Management

Management criteria checks 1/4

OncoSil Medical's CEO is Nigel Lange, appointed in Jan 2021, has a tenure of 3.67 years. total yearly compensation is A$638.57K, comprised of 60.8% salary and 39.2% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth A$86.62K. The average tenure of the management team and the board of directors is 3.6 years and 1.1 years respectively.

Key information

Nigel Lange

Chief executive officer

AU$638.6k

Total compensation

CEO salary percentage60.8%
CEO tenure3.7yrs
CEO ownership0.2%
Management average tenure3.6yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

May 24
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Feb 03
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Oct 20
Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

May 13
OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Mar 21
OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

Jan 26
We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04
How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

CEO Compensation Analysis

How has Nigel Lange's remuneration changed compared to OncoSil Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-AU$12m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$12m

Jun 30 2023AU$639kAU$388k

-AU$11m

Mar 31 2023n/an/a

-AU$11m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$608kAU$388k

-AU$11m

Mar 31 2022n/an/a

-AU$11m

Dec 31 2021n/an/a

-AU$11m

Sep 30 2021n/an/a

-AU$11m

Jun 30 2021AU$964kAU$359k

-AU$10m

Compensation vs Market: Nigel's total compensation ($USD434.73K) is above average for companies of similar size in the Australian market ($USD310.14K).

Compensation vs Earnings: Nigel's compensation has increased whilst the company is unprofitable.

CEO

Nigel Lange

3.7yrs

Tenure

AU$638,572

Compensation

Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...

Leadership Team

NamePositionTenureCompensationOwnership
Nigel Lange
CEO, MD & Director3.7yrsAU$638.57k0.19%
A$ 86.6k
Christian Dal Cin
CFO & Company Secretary1.3yrsno datano data
Ralph Peters
Chief Medical Officer3.6yrsno datano data
David Turner
Head of Medical Affairs3.6yrsno datano data

3.6yrs

Average Tenure

Experienced Management: OSL's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nigel Lange
CEO, MD & Director3.7yrsAU$638.57k0.19%
A$ 86.6k
Peter Hall
Non-Executive Directorless than a yearno datano data
Douglas Cubbin
Chairman of the Board1.1yrsno datano data
Gabriel Liberatore
Non-Executive Director1.2yrsno datano data

1.1yrs

Average Tenure

Experienced Board: OSL's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.